Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Radius soars as Amgen sees mixed results for osteoporosis drug

Amgen's new osteoporosis treatment may not be as effective as a rival drug being developed by Radius.
Radius soars as Amgen sees mixed results for osteoporosis drug
Romo may generate sales of $1bn but faces competition from Radius’s experimental drug.

Shares in Radius Health (NASDAQ:RDUS) jumped by 27% as a rival osteoporosis treatment, romo, developed by Amgen (NASDAQ:AMGN) produced mixed results in a phase III trial.

The Amgen drug Romosozumab, or romo, achieved its primary endpoint of a significantly reduced risk of spinal fracture, but did not reduce breaks outside the spine area over longer period, its secondary endpoint.

Even so, Amgen and its Belgian partner UCB intend to file for regulatory approval later this year.

Analysts suggest Romo may generate sales of $1bn but faces competition from Radius’s experimental drug abaloparatide and also from an Eli Lily drug, Forteo, which comes off patent soon.

Abaloparatide reduced the risk of spinal fracture by 86% in its phase III trial compared to romo’s 73%, though it has to be injected daily compared to once a month with Amgen/UCB’s drug.

Amgen added that when combined over two years with Prolia, its current osteoporosis drug, the reduction rose to 75%.

Amgen said although Romo, designed to inhibit the protein sclerostin, reduced both spine and non-spine fractures in the first year, it did not repeat the performance in non-vertebral fractures in the second year.

Blocking sclerostin increases bone formation.

Shares in Amgen fell 2% to US$147.5 while Radius climbed US$7.24 to US$34.24.

PhilW.jpg


Register here to be notified of future RDUS Company articles

Related Articles

shutterstock_184785974.jpg
April 28 2016
Last year's acquisition of Kinesis Pharma meant that it could now offer a one-stop shop for its pharmaceuticals clients and expand its client base.
1-Operation.jpg
April 12 2016
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
cells_56ab78cfbeec5.jpg
January 29 2016
A return to Nasdaq and ongoing commercial success promises to address a significant disconnect in the valuation of Pressure Bioscience...

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.